eClinical Solutions LLC, a global leader in digital clinical software and services, is set to host its sixth annual client and partner conference, ENGAGE 2024, on Thursday, October 10 and…
Phare Bio, in collaboration with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, has secured up to $27 million in funding from the Advanced…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the positive…
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults.…
In recognition of World Dense Breast Day on September 25, Bayer has announced a new study, published in Patient Preference and Adherence, that explores gaps in awareness and knowledge of…
As British Columbians head to the polls on October 19, the Gastrointestinal Society is drawing attention to a critical issue: BC PharmaCare’s refusal to fund over 30 essential medications that…
Tennessee Governor Bill Lee, along with Economic and Community Development Commissioner Stuart C. McWhorter and Harrow, Inc. CEO Mark L. Baum, announced today that Harrow is expanding its corporate headquarters…
Fujirebio has announced that its subsidiary, Fujirebio Diagnostics, Inc., has submitted the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test to the U.S. Food and Drug Administration…
Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming pharmacy care delivery, has announced the appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024.…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has introduced Medidata Patient Payments, a new solution designed to simplify the process…
Takeda (TSE:4502/NYSE) has announced that the Japanese Ministry of Health, Labour and Welfare has approved the manufacture and marketing of FRUZAQLA Capsules (1mg/5mg), containing fruquintinib, a selective oral inhibitor targeting…
Zenyaku Kogyo Co., Ltd. (Japanese-only website) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) have announced that Zenyaku has received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW)…